Screen detected, low volume prostate cancer: The case for active treatment

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 5, 2008, Pages 511-515

  Montie, James E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Low volume; Prostate cancer; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; TUMOR VOLUME;

DISEASE PROGRESSION; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 50649099257     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.03.006     Document Type: Review

References (33)

1. Bill-Axelson A., Holmberg L., Ruutu M., et al. Treatment of pre-PSA detected cancer does decrease mortality in <65-year olds. NEJM 352 (2005) 1977-1984
2. Patel H.R.H., Mirsadraee S., and Emberton M. The patients' dilemma: Prostate cancer treatment choices. J Urol 169 (2003) 828-833
3. Clark J.A., and Talcott J.A. Confidence and uncertainty long after initial treatment for early prostate cancer: Survivors' views of cancer control and the treatment decisions they made. J Clin Oncol 24 (2006) 4457-4463
4. van Tol-Geerdink J.J., Stalmeier P., van Lin E., et al. Do patients with localized prostate cancer treatment really want more aggressive treatment?. J Clin Oncol 24 (2006) 4581-4586
5. Miller D.C., Gruber S.B., Hollenbeck B.K., et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. JNCI 98 (2006) 1134-1141
6. Siddiqui S.A., Sengupta S., Slezak J.M., et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 175 (2006) 952-957
7. Wong Y., Mitra N., Hudes G., et al. Survival associated with treatment vs. observation of localized prostate cancer in elderly men. JAMA 296 (2006) 2683-2693
8. Litwin M.S., and Mille D.C. Treating older men with prostate cancer. JAMA 296 (2006) 2733-2734
9. Coogan C.L., Latchamsetty K.C., Greenfield J., et al. Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score. BJU Int 96 (2005) 324-327
10. Mian B.M., Lehr D.J., Moore C.K., et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology 64 (2006) 379-383
11. Roemeling S., Roobol M.J., Postma R., et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50 (2006) 475-482
12. Arora R., Koch M., Eble J., et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100 (2004) 2362-2366
13. Moran B.J., Braccioforte M.H., and Conterato D.J. Rebiopsy of the prostate using a stereotactic transperineal technique. J Urol 176 (2006) 1376-1381
14. Martin R.M., Gunnell D., Hamdy F., et al. Continuing controversy over monitoring men with localized prostate cancer: A systematic review of programs in the prostate specific antigen era. J Urol 176 (2006) 439-449
15. Klotz L. Active surveillance for prostate cancer: For whom?. J Clin Oncol 23 (2005) 8165-8169
16. Tomlins S.A., Mehra R., Rhodes D.R., et al. Integrative molecular concept modeling of prostate cancer progression. Nature Genet 10 (2006) 1-11
17. Stamey T.A., McNea J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395-1400
18. Khoddami S.M., Shariat S.F., Lotan Y., et al. Predictive value of primary Gleason pattern four in patients with Gleason score 7 tumors treated with radical prostatectomy. BJU Int 94 (2004) 42-46
19. Whitmore W.F., Warner J.A., and Thompson I.M. Expectant management of localized prostatic cancer. Cancer 67 (1991) 1091-1096
20. Cowen M.E., Halasyamani L.K., and Kattan M.W. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 175 (2006) 99-103
21. Ballentine-Carter H, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. JNCI 98:1521-1527.
22. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
23. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23 (2005) 2918-2925
24. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 176:1392-8.
25. Xiaoying Y., Misop H., Loeb S., et al. Comparison of methods for calculating prostate specific antigen velocity. J Urol 176 (2006) 2427-2431
26. Onik G. The male lumpectomy: Rationale for a cancer targeted approach for prostate cryoablation. A review. Tech Cancer Res 3 (2004) 365-370
27. Mazur D.J., and Merz J.F. Older patients willing to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of prostate cancer. J Am Geriatr Soc 43 (1995) 979-984
28. Schwartz K.L., Alibhai S.M.H., Tomlinson G., et al. Continued undertreatment of older men with localized prostate cancer. Urology 62 (2003) 860-865
29. Davison B.J., Parker P.A., and Goldenberg S.L. Patients' preference for communicating a prostate cancer diagnosis and participating in medical decision-making. BJU Int 93 (2004) 47-51
30. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146-8151
31. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organization for Research and Treatment of Cancer (EORTC) Trial 3081. J Clin Oncol 24 (2006) 1868-1876
32. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
33. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456